Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

LY4257496

Radiopharmaceutical · Kills target cells, directed at gastrin-releasing peptide receptor (GRPR) · developed by ELI LILLY &

Phase 1 Most advanced trial
LLY Developer

What is LY4257496?

LY4257496 is a radioconjugate made of a gastrin-releasing peptide receptor (GRPR)-targeting ligand carrying a cytotoxic radioisotope. It binds GRPR-expressing tumor cells to deliver a cytotoxic radiation dose to them. It is being studied in breast, colorectal, prostate, endometrial, gastric and esophageal neoplasms.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Radiopharmaceutical
Targets
gastrin-releasing peptide receptor (GRPR)
Mechanism
Kills target cells, directed at gastrin-releasing peptide receptor (GRPR)
Therapy area
Oncology
Developer
ELI LILLY & (LLY)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

Conditions studied

Breast NeoplasmsColorectal NeoplasmsEndometrial NeoplasmsEsophageal NeoplasmsNeoplasm MetastasisProstate NeoplasmStomach Neoplasms

More from ELI LILLY &

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the LLY page.

Follow LLY, the company behind LY4257496

See LLY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

LLY catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.